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Abstract:  27 
Context: primary hyperparathyroidism (PHPT) has been related to bone loss. Dual-energy X-28 
ray absorptiometry (DXA) cannot distinguish between trabecular and cortical bone 29 
compartments but the recently developed 3D-DXA software might overcome this issue.  30 
Objective: to examine the differences in DXA-derived areal bone mineral density (aBMD) and 31 
3D-DXA parameters at the hip site between patients with PHPT and a healthy control group. 32 
Design: cross-sectional pilot study 33 
Setting: hospital 34 
Patients: 80 adults (59.5 ± 9.1 yrs), 40 with PHPT and 40 healthy age- and sex-matched healthy 35 
controls. 36 
Measures: aBMD (g/cm2) of the femoral neck, trochanter, shaft and total hip was assessed 37 
using DXA. Cortical surface (sBMD, mg/cm2), cortical volumetric BMD (vBMD, mg/cm3), 38 
trabecular vBMD (mg/cm3), integral vBMD (mg/cm3) and cortical thickness (mm) was 39 
assessed using 3D-DXA software. 40 
Results: mean-adjusted values showed lower aBMD (7.5% to 12.2%, effect size: 0.51-1.01) in 41 
the PHPT group compared to the control group (all p<0.05). 3D-DXA revealed bone 42 
impairment (3.7% to 8.5%, effect size: 0.47-0.65) in patients with PHPT, mainly in cortical 43 
parameters (all p<0.05). However, differences in trabecular vBMD were not statistically 44 
significant (p=0.055). The 3D mapping showed lower cortical sBMD, cortical vBMD and 45 
cortical thickness at the trochanter and diaphysis in the PHPT group (p<0.05) compared to the 46 
control group. In both groups, the presence of osteopenia or osteoporosis is related to lower 47 
cortical bone. 48 
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Conclusions: aBMD and cortical 3D parameters are impaired in patients with PHPT versus 49 
healthy controls. The vBMD of the trabecular compartment seems to be affected though to a 50 
lower extent. 51 




Primary hyperparathyroidism (PHPT) is a common endocrine disorder characterized by 54 
hypercalcemia and parathyroid hormone (PTH) levels that are elevated or inappropriately 55 
normal (1, 2). In 80% of the cases, a single gland disorder causes the excessive secretion of 56 
PTH while in the remaining; a multiple gland disorder is the cause (1). In the United States, the 57 
prevalence of PHPT is higher in women (23 cases per 10,000 women) than in men (8.5 cases 58 
per 10,000 men) (3) and the condition has frequently been related to bone fragility.   59 
Patients with PHPT present high rates of bone remodelling and a slow decline in bone mass. 60 
Findings from a 15-year observational study showed that the areal bone mineral density 61 
(aBMD) of the femoral neck and radius decreased while that of the lumbar spine was preserved 62 
(4). In a study with 52 patients with PHPT (5), the most important reductions in aBMD were 63 
found at the radius, a site of predominantly cortical bone whereas normal aBMD was found at 64 
the lumbar spine, a site of predominantly trabecular bone. With regards to femoral neck aBMD 65 
(mix of cortical and trabecular bone), 23% of the patients with PHPT had values that were lower 66 
than those of 80% of their age- and sex-matched healthy peers (5). Percutaneous bone biopsies 67 
confirmed the impairment of cortical bone with apparent preservation of trabecular bone in 68 
PHPT (5), which was backed up in other studies (6, 7). However, with the arrival of new and 69 
more precise technologies the way these findings were looked at changed. Studies using 70 
peripheral quantitative computed tomography (pQCT) showed a catabolic effect of PTH on 71 
both trabecular and cortical bone compartments (8, 9). Interestingly, a study using high-72 
resolution pQCT (HRpQCT) suggested that mechanical loading helped to counteract the 73 
detrimental effects of PTH on trabecular bone of the tibia (not in the radius), but it did not ward 74 
off the loss of cortical bone in PHPT (10).  75 
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Epidemiology studies suggest that PHPT is associated to an increased overall risk of fracture 76 
(10, 11). Dual energy X-ray Absorptiometry (DXA) is considered the gold standard method for 77 
assessing aBMD by non-invasive means in a clinical setting and has been used worldwide in 78 
numerous population groups of different ages (12). It is also a valid method to diagnose 79 
osteoporosis and to predict the risk of fracture in adults (13), with special relevance to those of 80 
the femur due to the high prevalence of fractures at this site (14). As a limitation, DXA cannot 81 
distinguish between trabecular and cortical bone compartments DXA due to its limited 82 
resolving power (10). Advanced techniques, such as pQCT or HRpQCT enable in vivo 83 
assessment of trabecular and cortical bone microarchitecture but they are very expensive and 84 
only available in few laboratories worldwide. Therefore, combining DXA-derived aBMD data 85 
with 3D QCT-like parameters of cortical and trabecular bone would be an alternative in clinical 86 
settings. In this study, we not only used aBMD of hip sites but also the recently developed 3-87 
dimensional (3D)-DXA software algorithm to quantify the cortical thickness and the 88 
volumetric bone mineral density (vBMD) of the cortical and trabecular bone compartments, 89 
among other parameters. This method models the femoral neck and the bone density 90 
distribution, and assesses the trabecular macrostructure and the cortex in 3D using an 91 
anteroposterior DXA projection (15). The accuracy of the 3D-DXA models and measurements 92 
has been evaluated using a database with 157 subjects and comparing the 3D-DXA analyses 93 
with QCT measurements (15). The 3D-DXA parameters have shown very strong correlations 94 
compared to QCT outcomes and are therefore, a feasible alternative when pQCT is not available 95 
(16).  96 
In this pilot study, we aimed to examine between-group differences in DXA-derived aBMD 97 
and 3D-DXA parameters at the hip site between patients with PHPT and a healthy control 98 
group. Additionally, we aimed to examine within-group differences in 3D-DXA parameters 99 
according to the World Health Organization criteria for osteoporosis and osteopenia. We 100 
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hypothesized that patients with PHPT would present poorer bone health than controls and that 101 
both cortical and to a lower extent trabecular vBMD, would be affected. 102 
Material and methods 103 
Study design and participants 104 
The current cross-sectional pilot study includes data from 80 adults (59.5 ± 9.1 years old, 58 105 
females) from Granada (Spain). Data were obtained between 2016 and 2017 at the 106 
Endocrinology Unit of the University Hospital San Cecilio of Granada. Forty patients (n=40) 107 
with PHPT, having hypercalcemia (mean and standard deviation: 10.7±0.5 mg/dL) and elevated 108 
PTH levels (mean and standard deviation: 114.9±40.8 mg/dL), were included. None of them 109 
had osteitis fibrosa cystica. Early menopause, familial hypocalciuric hypercalcemia and the use 110 
of glucocorticoids, bisphosphonates or other antiresorptive treatment in the two years before 111 
inclusion were considered exclusion criteria.  112 
An age- and sex-matched healthy control group (n=40) was also recruited. None of the 113 
participants presented, at the moment of recruitment, diseases known to affect bone 114 
metabolism. Early menopause, a history of previous fragility fracture and the use of 115 
glucocorticoids, bisphosphonates or other antiresorptive treatment in the two years before 116 
inclusion were considered exclusion criteria.  117 
The study was conducted according to the Declaration of Helsinki and the approval of the Ethics 118 
Committee of the Provincial Biomedical Research of Granada. Informed consent was obtained 119 
from all participants. 120 
 121 
Outcome measures 122 
Areal bone mineral density  123 
A left hip scan using a Hologic QDR 4500 densitometer (Hologic Series Discovery QDR, 124 
Bedford, MA, USA) was used to measure aBMD at the femoral neck, trochanter, shaft and total 125 
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hip. Of note, the shaft location was defined along a line 2cm distal to the user located midpoint 126 
of the lesser trochanter, measured along the shaft axis (17). In addition, we used the World 127 
Health Organization criteria for osteoporosis and osteopenia (18). All DXA scans and analyses 128 
were performed by the same experienced operator following recommendations from the 129 
International Society of Clinical Densitometry (19). The DXA equipment was calibrated on a 130 
daily basis using a spine phantom. The coefficients of variation within our laboratory were 1.8% 131 
and 1.5% for the femoral neck and total hip, respectively. Moreover, the coefficients of 132 
variation in a previous study with men and women over the age of 60 years were 2.13% and 133 
3.14% for the shaft and trochanter, respectively (20). 134 
 135 
3D-DXA modeling 136 
The 3D-Shaper software (version 2.2, Galgo Medical, Barcelona, Spain) was used to assess the 137 
trabecular macrostructure, the cortex and femoral shape from DXA scans of the PHPT and 138 
control groups. Detailed information of the modelling method used in the software has been 139 
published elsewhere (15). Briefly, this method is based on a statistical shape and density model 140 
of the proximal femur generated from a database of QCT scans of Caucasian women and men 141 
(15). The 3D model is registered onto the DXA scan in order to obtain a 3D QCT-like 142 
participant-specific model of the proximal femur shape and BMD distribution. The cortical 143 
thickness and density is computed by fitting a mathematical function to the density profile 144 
computed along the normal vector at each node of the proximal femur surface mesh (21). The 145 
cortical thickness (mm) and the vBMD (mg/cm3) of the trabecular, cortical, and integral bone 146 
compartments of the total femur was computed (22). In addition, the cortical surface BMD 147 
(sBMD, mg/cm2) at each vertex of the femoral surface mesh is computed as the product 148 
between cortical thickness (cm) and the cortical vBMD (mg/cm3) along its thickness (16). 149 
Cortical sBMD, cortical vBMD and cortical thickness measure the cortical compartment, while 150 
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trabecular vBMD measures the density of the trabecular compartment. Integral vBMD 151 
measures the integral compartment, being the union of the trabecular and cortical 152 
compartments. All measurements are performed at the total femur region of interest. The 153 
correlations between QCT and 3D-DXA for integral vBMD, trabecular vBMD, cortical vBMD 154 
and cortical thickness were 0.95, 0.86, 0.93 and 0.91, respectively (15). The coefficients of 155 
variation for cortical thickness, trabecular vBMD, cortical vBMD and cortical sBMD were 156 
1.5%, 4.5%, 1.7% and 1.5% (16).  157 
 158 
Anthropometric measures 159 
Weight (kg) and stature (cm) were measured with an electronic scale (SECA 861 and 760, 160 
Hamburg, Germany) and a stadiometer (SECA 225 and 220, Hamburg, Germany), respectively. 161 
The body mass index (BMI) was calculated as: weight (kg)/stature (m2). 162 
 163 
Serum measurements 164 
Venous blood samples were obtained by venipuncture after an overnight fast. Serum 165 
parathormone (PTH, pg/mL) was measured using two-site immunoassay for PTH (Roche 166 
Diagnostics SL, Barcelona, Spain). Calcium (mg/dL, adjusted for serum albumin) was 167 
measured using standard automated laboratory techniques. Normal levels for calcium range 168 
between 8.8 and 10.2 mg/dL and for PTH between 12-88 pg/mL. 169 
 170 
Statistical analysis 171 
Data were analyzed using SPSS IBM statistics (version 20 for Windows, Chicago, IL) and the 172 
significance level was set at p<0.05. The distribution of variables was checked and verified 173 
using Kolmogorov-Smirnov test, skewness and kurtosis values, visual check of histograms, Q-174 
Q and box plots.  175 
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Descriptive analyses comparing the PHPT and control groups were performed by independent 176 
samples T-test (for continuous variables) or chi-square test (for categorical variables).  177 
Analysis of covariance (ANCOVA) was used to examine differences in the outcome variables 178 
(aBMD and 3D-DXA parameters) between the PHPT and control groups. Sex, age and BMI 179 
were used as covariates. The effect size (ES, Cohen’s d) is also provided and the interpretation 180 
is: 0.2 small, 0.5 medium and 0.8 large (23). Percentages of difference between groups for the 181 
significant variables in the ANCOVA analysis were used to quantify the magnitude of the 182 
differences. 3D spatial distribution of differences between PHPT and control groups in the 183 
cortical bone (cortical sBMD, cortical vBMD and cortical thickess) were computed.  184 
Finally, the discrimination of bone status (normal, osteopenia, osteoporosis) by 3D-DXA 185 
measurements in patients with PHPT and controls was performed using ANCOVA and 186 
including sex, age and BMI as covariates. 187 
 188 
Results 189 
Table 1 shows descriptive characteristics of the participants in the PHPT and control groups. 190 
The proportion of males (27.5%) and females (72.5%) was the same in both groups and the 191 
higher number of females reflects the higher prevalence of PHPT. The recruited groups were 192 
very homogenous and there were no differences between them in age, height, weight and BMI 193 
(all p>0.05). Crude aBMD and 3D-DXA parameters of the cortical sBMD, integral vBMD and 194 
cortical thickness were significantly lower in the PHPT group compared to the control group 195 
(all p<0.05).  196 
Table 2 presents mean-adjusted (by age, sex and BMI) differences in aBMD and 3D-DXA 197 
parameters between groups. aBMD was significantly lower in the PHPT group compared to the 198 
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control group at all sites: femoral neck (p=0.023, ES=0.51), trochanter (p=0.001,  ES=0.75), 199 
shaft (p<0.001, ES=0.91) and total hip (p<0.001, ES=1.01). More specifically, the aBMD was 200 
7.5%, 10.2%, 11.7% and 12.2% lower in the PHPT group compared to the control group at the 201 
femoral neck, trochanter, shaft and total hip, respectively (Figure 1). 3D-DXA parameters 202 
showed poorer cortical sBMD (p=0.005, ES=0.65), cortical vBMD (p=0.037, ES=0.47), 203 
integral vBMD (p=0.022, ES=0.52) and cortical thickness (p=0.011, ES=0.63) in the PHPT 204 
group compared to the control group. However, the difference between groups in trabecular 205 
vBMD did not reach statistical significance (p=0.055). More specifically, the cortical sBMD, 206 
cortical vBMD, integral vBMD and cortical thickness of the PHPT was 4.3%, 8.4%, 3.7%, and 207 
8.5% lower than the control group (Figure 1).  208 
3D mapping showing the anatomical distribution of differences between groups in the cortical 209 
compartment indicates that the PHPT group had significantly lower cortical sBMD, cortical 210 
vBMD and cortical thickness at the trochanter and diaphysis (p<0.05), while differences at the 211 
femoral neck were not statistically significant (Figure 2). 212 
Finally, patients with PHPT and diagnosed with osteoporosis or osteopenia had significantly 213 
lower cortical vBMD compared to those with normal bone values (Figure 3). For the rest of the 214 
3D-DXA outcomes, lower values were also observed with increasing bone deterioration 215 
however; a statistical significance was not reached (p>0.05). With regards to the control group, 216 
those diagnosed with osteopenia had significantly lower cortical sBMD, cortical vBMD, 217 
integral vBMD and cortical thickness compared to those with normal bone density values 218 





Our pilot study is the first combining hip DXA-derived and 3D-DXA outcomes of cortical and 222 
trabecular bone to examine differences between PHPT patients and healthy controls. The main 223 
findings of the present study show that: 1) the aBMD of the femoral neck, trochanter, shaft, and 224 
total hip was significantly lower in PHPT patients compared to the control group; 2) the 3D-225 
DXA parameters involving cortical bone compartments (cortical sBMD, cortical vBMD, 226 
integral vBMD and cortical thickness) were significantly lower in PHPT patients than the 227 
control group while a trend for a lower trabecular vBMD was also observed in this group, which 228 
is consistent with our hypothesis. The ES of the differences observed between PHPT and 229 
healthy controls ranged from 0.51 to 1.01 (for aBMD parameters) and from and 0.47 to 0.65 230 
(for 3D-DXA parameters), suggesting a medium to large effect sizes.  231 
From a DXA point of view, in patients with PHPT trabecular bone is relatively preserved while 232 
cortical bone is largely affected. Therefore, lower aBMD is usually observed in PHPT patients 233 
compared to controls at the hip or radius (4-7), sites with a high proportion of cortical bone. 234 
Our findings on the catabolic effects of excess PTH on aBMD agree with those from the study 235 
of Rubin et al (4), in which declines in femoral neck aBMD were evident in patients with PHPT. 236 
Similarly, a study conducted in elderly men with PHPT observed lower aBMD at the total hip 237 
(~7%), femoral neck (7.7%) and trochanter (11.6%) compared to a control group without the 238 
disease (24). This approach is based on the catabolic action of PTH on cortical bone, acting on 239 
osteocytes, osteoblasts and osteoclasts and increasing bone remodelling in favour of bone 240 
resorption (25) to ultimately, result in bone loss (26). 241 
Recent scientific evidence using more advanced techniques and devices have shown trabecular 242 
bone deterioration assessed by TBS (27-29), pQCT (8, 9) and HRpQCT (10, 30-32) in patients 243 
with PHPT. In this regard, we recently showed TBS to reflect degraded bone structure and 244 
diagnose bone fragility in patients with PHPT better than aBMD (33), a finding that is consistent 245 
with a study using HRpQCT (10). Therefore, the catabolic effects of PTH in both cortical and 246 
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trabecular bone seem now to be evident as shown in a HRpQCT study (10). In the present study, 247 
using 3D-DXA parameters (more affordable than QCT devices) we have observed deterioration 248 
of cortical bone and a non-significant deterioration of trabecular bone. Our data suggest reduced 249 
vBMD of mainly cortical and to a lower extent trabecular (though non-significant) 250 
compartments, thinner cortices and also reduced sBMD, a highly accurate indicator of cortical 251 
bone strength (34). Our 3D-DXA findings are consistent with those reported in studies using 252 
HRpQCT (10, 35) in PHPT patients. In addition, the non-significant (but borderline) deleterious 253 
effect of PHPT on trabecular vBMD in the present study can be partially explained by the 254 
compensatory effect of mechanical loading which is very likely to have a protective effect in 255 
the hip (36), and is known to preserve the loss of trabecular bone (10). In addition, the relatively 256 
small sample size might have contributed to this non-statistically significant finding.  257 
Our 3D mapping shows that the greatest differences in cortical vBMD, cortical sBMD and 258 
cortical thickness between groups are in the trochanteric area rather than the femoral neck, 259 
which might suggest a greater risk of fractures in this site. Previous studies have found a higher 260 
but statistically non-significant risk of fracture at the proximal femur and femoral neck in 261 
patients with PHPT compared to those without the condition (37, 38), backing up our findings. 262 
In addition, Fischer et al. observed the presence of (secondary) hyperparathyroidism in 30.2% 263 
of the patients with femoral neck fracture and in 41.3% of those with trochanteric fracture. 264 
Interestingly, PTH was significantly higher in patients with trochanteric fracture than in those 265 
with the femoral neck fracture (39), supporting the role of PTH in site-specific fractures.  266 
Finally, our data also suggest that patients with PHPT with osteopenia or osteoporosis had their 267 
femoral neck cortical bone more impaired than those with normal bone density. However, 268 
trabecular bone and cortical thickness did not differ according to the bone diagnosis. These 269 
findings support the fact that the presence of osteopenia or osteoporosis is due to the greater 270 
bone deterioration of the cortical bone compartment of the femoral neck. This agrees with the 271 
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studies of Bandeira et al. (40) in which cortical osteoporosis was found at the femoral neck in 272 
patients with PHPT and the recent study of Osima et al. (41) in which PTH was associated with 273 
increased femoral cortical subtrochanteric cortical porosity in postmenopausal women. 274 
However, we only had 5 patients (12.5%) with PHPT with normal bone density which may 275 
have (negatively) affected comparisons. With regards to the healthy control group, our data 276 
suggest that those with osteopenia had their cortical and trabecular bone more impaired than 277 
those with normal bone density. It is important to highlight that since we recruited a healthy 278 
control group, none control participants had osteoporosis. Therefore, sample sizes are more 279 
even for normal bone density (n=23) and osteopenia (n=17) enabling more solid comparisons.  280 
Our findings suggest that the combination of aBMD with 3D-DXA parameters may be useful 281 
for clinicians wishing to evaluate bone health in everyday practice at the hip site in patients 282 
with PHPT. Despite the guidelines for the management of asymptomatic primary 283 
hyperparathyroidism recommended lumbar spine, hip and forearm scans in patients with PHPT 284 
(42), there is evidence showing that the forearm is not routinely assessed and therefore, a 285 
substantial but unrecognized bone loss may be present (43). The 3D-DXA derived parameters 286 
may provide useful information on cortical bone and complement the forearm scan. This is 287 
important since other technique, such as HRpQCT is only available in a few places worldwide 288 
and unlikely to become widely used (44).  289 
Strengths and limitations 290 
Our study is the first to report 3D-DXA outcomes and compare cortical and trabecular bone 291 
and quantify the differences between PHPT patients and healthy controls using an approach 292 
based on 3D QCT-like participant-specific models of the proximal femur shape and BMD 293 
distribution. Despite the sample size is relatively small the recruitment of an age- and sex-294 
matched control group ensured having two very homogenous groups. In our study the 295 
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proportion of males and females with PHPT in both groups was 27.5% and 72.5%, respectively. 296 
This was expected since the prevalence of the disease is almost triple in females (3). 297 
As limitations, the cross-sectional design precludes any determination of causality in our 298 
findings. However, whilst the catabolic effect of PTH on bone mass has been described, the 299 
mechanisms by which a greater or lower bone mass could affect PTH concentrations are 300 
unknown. In addition, we only had 5 patients with PHPT with a normal densitometric diagnosis 301 
and this may have affected our results on the differences in 3D-DXA parameters according to 302 
DXA bone diagnosis. This might explain why significant differences were only found for the 303 
cortical vBMD but not for the rest of the parameters in the PHPT group while significant 304 
differences were observed in all parameters of the control group (n with normal bone = 23). 305 
Moreover, we recruited a healthy control group and none of them had osteoporosis. This has to 306 
be kept in mind when interpreting the between-group and within-group differences from this 307 
study. Finally, since information on lifestyle behaviours such as exercise, nutrition or tobacco 308 
smoking among others was not collected, we cannot rule out the possibility that these factors 309 
contributed to the existing differences described in this study. Future longitudinal studies, 310 
including osteoporotic controls and assessing fracture risk are warranted to test the potential of 311 
3D-DXA in clinical settings.   312 
 313 
Conclusions 314 
The findings indicate that patients with PHPT have lower aBMD at the hip sites and reduced 315 
cortical 3D parameters compared to an age- and sex-matched healthy control group. In addition, 316 
the vBMD of the trabecular compartment seems to be affected though to a lower extent. 317 
Longitudinal studies including fracture assessment are needed to confirm the usefulness of 3D-318 
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Figure 1. Significant differences (%) in adjusted (by age, sex and body mass index) areal bone 466 
mineral density (aBMD, g/cm2) and 3D-DXA parameters between patients with primary 467 
hyperparathyroidism (PHTP, n=40) and the healthy control group (n=40). * denotes a 468 
significant difference relative to the control group (p<0.05) 469 
 470 
Figure 2. Distribution of the average differences (p < 0.05) in (A) cortical surface bone mineral 471 
density (cortical sBMD), (B) cortical volumetric bone mineral density (cortical vBMD) and (C) 472 
cortical thickness of the total femur region in the primary hyperparathyroidism (PHTP, n=40) 473 
group relative to the healthy control group (n=40). Regions with no significant differences are 474 
coloured in grey (p>0.05). 475 
 476 
Figure 3. 3D-DXA parameters of patients with primary hyperparathyroidism (PHTP, n=40) 477 
and the healthy control group (n=40) according to the World Health Organization criteria for 478 
osteoporosis and osteopenia. White bars = normal bone density; grey bars = osteopenia and 479 
black bars = osteoporosis. Results (mean and standard error) are adjusted by age, sex and body 480 
mass index.  481 
PHPT group: Normal bone density (n=5), osteopenia (n=15) and osteoporosis (n=20). 482 
Healthy control group: Normal bone density (n=23), osteopenia (n=17) and osteoporosis (n=0). 483 
* denotes within-group significant differences (p<0.05) versus normal bone density. 484 
